Psoriasis is a chronic immune-mediated skin disease with a significant impact on patients’ quality of life. Mild-to-moderate forms of the disease usually require long-term topical treatment, but prolonged use of corticosteroids and vitamin D analogues is limited by adverse effects. With further understanding of psoriasis pathogenesis, new molecules are emerging aiming to fulfil these clinical needs. Tapinarof, an aryl hydrocarbon receptor inhibitor, has completed a phase III study and demonstrated good efficacy results, even in long treatment courses, with a favourable safety profile. It additionally appears to have a promising remitting effect as patients presented with an average relapsing time of over 3 months. Roflumilast, a phosphodiesterase type 4 inhibitor, also underwent a phase III study with significant lesion improvement and notable pruritus management, and with no reported side effects. Roflumilast was evaluated as an option for intertriginous areas with good outcomes in a small sample, but larger trials are required. The Janus kinase-signal transducer and activator of transcription pathway has been targeted in recent clinical investigations with promising options, currently with brepocitinib pending phase IIb results. Ongoing preclinical studies involving interleukin-2 inhibition, RNA modulators and amygdalin analogues may lead to forthcoming clinical trials. New topical drugs are successfully emerging and future research comparing them to classical options will dictate their clinical role in the treatment of psoriasis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60. https://doi.org/10.1001/jama.2020.4006.
Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020;31(5):470–5. https://doi.org/10.1080/09546634.2020.1746734.
González-Parra S, Daudén E. Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr. 2019;110(1):12–9. https://doi.org/10.1016/j.ad.2018.05.009.
Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91. https://doi.org/10.1038/jid.2014.530.
Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–13. https://doi.org/10.4049/jimmunol.1800013.
Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, et al. The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616–26. https://doi.org/10.1111/ijlh.12426.
Bergboer JGM, Zeeuwen PLJM, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol. 2012;132(10):2320–31. https://doi.org/10.1038/jid.2012.167.
Gelfand JM, Gordon KB, Gottlieb A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60(4):643–59. https://doi.org/10.1016/j.jaad.2008.12.032.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057.
Kelly A, Ryan C. Genital psoriasis: impact on quality of life and treatment options. Am J Clin Dermatol. 2019. https://doi.org/10.1007/s40257-019-00447-5.
Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;e12589:1–15. https://doi.org/10.1111/dth.12589.
Griffiths CEM, Gold LS, Cambazard F, Lowson D, Møller A, Paul C. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol. 2018;28(3):356–63. https://doi.org/10.1684/ejd.2018.3302.
Paul C, Gold LS, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–26. https://doi.org/10.1111/jdv.13859.
Kragballe K, Gjertsen BT, De Hoop D, Karlsmark T, van de Kerkhof PC, Larkö O, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:193–6.
Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54(4):383–92. https://doi.org/10.1111/ijd.12790.
Selmer J, Vestbjerg B, Præstegaard M, Gold LS. Phase 3 trial demonstrates that MC2-01 cream has improved treatment efficacy compared to calcipotriene plus betamethasone dipropionate topical suspension in patients with mild to moderate psoriasis vulgaris. Skin J Cutan Med. 2020;4(5): s36. https://doi.org/10.25251/skin.4.supp.36.
Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris: a randomized phase II study. J Dermatolog Treat. 2016;27(2):120–7. https://doi.org/10.3109/09546634.2015.1083935.
Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–93. https://doi.org/10.1016/j.jaad.2018.03.040.
Lebwohl MG, Stein Gold L, Papp K, et al. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol Venereol. 2021;35(5):1152–60. https://doi.org/10.1111/jdv.17113.
Boehncke W, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7.
Belichón I, Blanch C, Rivera R, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–67.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1–28. https://doi.org/10.3390/ijms20061475.
Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059–67. https://doi.org/10.1016/j.jaad.2020.10.085.
Furue M, Hashimoto-hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424.
Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–9. https://doi.org/10.1016/j.jid.2017.05.004.
Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516–21. https://doi.org/10.1111/j.1468-3083.2011.04332.x.
Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–21. https://doi.org/10.1016/j.jaad.2018.10.037.
Stein Gold L, Bhatia N, Tallman AM, Rubenstein DS. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2021;84(3):624–31. https://doi.org/10.1016/j.jaad.2020.04.181.
Stein Gold L, Strober B, Armstrong A, Hong HCH, Kircik L, Soung J, et al. Tapinarof cream 1% QD for the treatment of plaque psoriasis: efficacy and safety in two pivotal phase 3 trials. D3T03.3D, EADV Virtual, 29–31 October 2020. https://aad-eposters.s3.amazonaws.com/VMX2021/poster/25750/Tapinarof+Cream+1+Once+Daily+for+Plaque+Psoriasis+Secondary+Efficacy+Outcomes+from+Two+Pivotal+Phase+3+Trials.pdf. Accessed 22 Oct 2021.
Lebwohl M, Stein Gold L, Strober B, Armstrong A, Hong HCH, Kircik L, et al. Tapinarof cream 1% QD for the treatment of plaque psoriasis: efficacy and safety in two pivotal phase 3 trials. Ski J Cutan Med. 2020;4(6): s75. https://doi.org/10.25251/skin.4.supp.75.
Strober B, Gold LS, Bissonnette R, Armstrong A, Blauvelt A, Kircik L, et al. Tapinarof cream 1% once daily for plaque psoriasis: a long-term extension trial of a novel therapeutic aryl hydrocarbon receptor modulating agent [abstract 2860]. EADV 30th Congress; 2021.
Cai L, Chen G, Lu Q, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 2020;133(24):2905–9. https://doi.org/10.1097/CM9.0000000000001221.
Li H, Zuo J, Tang W. Phosphodiesterase-4 (PDE4) inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048. https://doi.org/10.3389/fphar.2018.01048.
Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229–39. https://doi.org/10.1056/nejmoa2000073.
Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32. https://doi.org/10.1007/s40257-017-0302-0.
Snape SD, Wigger-Alberti W, Goehring UM. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Br J Dermatol. 2016;175(3):479–86. https://doi.org/10.1111/bjd.14634.
Lebwohl M, Kircik LH, Moore A, Gold LS, Del Rosso J, Draelos ZD, et al. Once-daily roflumilast cream 0.3%, a potent phosphodiesterase-4 inhibitor, provided safe and effective treatment of psoriasis in the DERMIS-1 and DERMIS-2 phase 3 trials [abstract 2063]. EADV 30th Congress; 2021.
Gooderham MJ, Alonso-Llamazares J, Bagel J, Brownigh JC, Draelos ZD, Grande KK, et al. Roflumilast cream 0.3% improved the severity and impact of itch in patients with chronic plaque psoriasis in the phase 3 DERMIS-1 and DERMIS-2 studies [abstract 146]. EADV 30th Congress; 2021.
Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2020;82(2):360–5. https://doi.org/10.1016/j.jaad.2019.06.1288.
Rafael A, Torres T. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol. 2016;26(1):3–8. https://doi.org/10.1684/ejd.2015.2663.
Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014;2014: 283617. https://doi.org/10.1155/2014/283617.
Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–52. https://doi.org/10.1007/s40265-020-01261-8.
Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535–44. https://doi.org/10.1016/j.jaad.2018.04.018.
Punwani N, Scherle P, Bsn RF, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Dermatol. 2012;67(4):658–64. https://doi.org/10.1016/j.jaad.2011.12.018.
Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol. 2015;173:989–97. https://doi.org/10.1111/bjd.13994.
Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949–61. https://doi.org/10.1111/bjd.14018.
Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45. https://doi.org/10.1111/bjd.12266.
Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16(15):1–12. https://doi.org/10.1186/s12895-016-0051-4.
Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020;140(12):2359-70.e5. https://doi.org/10.1016/j.jid.2020.03.962.
Smith SH, Peredo CE, Takeda Y, et al. Development of a topical treatment for psoriasis targeting RORγ: from bench to skin. PLoS ONE. 2016;11(2):1–18. https://doi.org/10.1371/journal.pone.0147979.
Ecoeur F, Weiss J, Kaupmann K, Hintermann S. Antagonizing retinoic acid-related-orphan receptor gamma activity blocks the T helper 17/interleukin-17 pathway leading to attenuated pro-inflammatory human keratinocyte and skin responses. Front Immunol. 2019;10:577. https://doi.org/10.3389/fimmu.2019.00577.
Kang EG, Wu S, Gupta A, et al. A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test. Br J Dermatol. 2018;178(6):1427–9. https://doi.org/10.1111/bjd.16131.
Otake S, Otsubaki T, Uesato N, Ueda Y, Murayama T, Hayashi M. Topical application of BMS-509744, a selective inhibitor of interleukin-2-inducible T cell kinase, ameliorates imiquimod-induced skin inflammation in mice. Biol Pharm Bull. 2021;44(4):528–34. https://doi.org/10.1248/bpb.b20-00850.
Guo S, Zhang W, Weia C, et al. Serum and skin levels of miR-369-3p in patients with psoriasis and their correlation with disease severity. Eur J Dermatol. 2013;23(5):608–13. https://doi.org/10.1684/ejd.2013.2148.
Zhang W, Yi X, An Y, et al. MicroRNA-17-92 cluster promotes the proliferation and the chemokine production of keratinocytes: implication for the pathogenesis of psoriasis. Cell Death Dis. 2018;9:5. https://doi.org/10.1038/s41419-018-0621-y.
Pradyuth S, Rapalli VK, Gorantla S, Waghule T, Dubey SK, Singhvi G. Insightful exploring of microRNAs in psoriasis and its targeted topical delivery. Dermatol Ther. 2020;33(6):1–9. https://doi.org/10.1111/dth.14221.
Wu R, Zeng J, Yuan J, et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest. 2018;128(6):2551–68. https://doi.org/10.1172/JCI97426.
Feng H, Wu R, Zhang S, et al. Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice. J Dermatol. 2020;47(2):147–54. https://doi.org/10.1111/1346-8138.1514.9.
Volpe E, Pattarini L, Martinez-Cingolani C, Meller S. Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis. J Allergy Clin Immunol. 2014;134(2):373-81.e4. https://doi.org/10.1016/j.jaci.2014.04.022.
López NG, Lagunas C, Juan A, Erwin JP. Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model. Exp Dermatol. 2020. https://doi.org/10.1111/exd.14390.
No funding has been received for the preparation of this article.
Conflicts of interest
Ana Maria Lé has no conflicts of interest to declare. Tiago Torres declares the following conflicts of interest: AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB.
Consent to Participate
Consent for Publication
Availability of Data and Material
AL and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.
About this article
Cite this article
Lé, A.M., Torres, T. New Topical Therapies for Psoriasis. Am J Clin Dermatol (2021). https://doi.org/10.1007/s40257-021-00649-w